Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Status:	Completed
Conditions:	Skin Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	9/15/2018
Start Date:	February 17, 2012
End Date:	August 17, 2017

A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma

The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will
extend the lives of subjects with unresectable or metastatic melanoma more than giving
Ipilimumab at a dose of 3 mg/kg

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Unresectable Stage III or Stage IV melanoma

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

- Brain metastases with symptoms or requiring treatment

- History of autoimmune disease

We found this trial at

sites

Providence Portland Medical Center

4805 Northeast Glisan Street
Portland, Oregon 97213

(503) 215-1111